Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Narrative (Details)

v3.23.1
Commitments and Contingencies - Narrative (Details)
 3 Months Ended
Jul. 19, 2022
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
May 01, 2021
periods
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Renewal options | periods       4
Renewal period (in years)       1 year
Agreement term (in days)       90 days
License agreement term (in days) 10 days      
General and administrative expense   $ 8,298,000 $ 7,824,000  
License Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
General and administrative expense   $ 200,000    
License Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Upfront license fee $ 50,000      
License or royalty net revenue percentage 3.00%      
Royalty expense $ 250,000      
License Agreement | Phase 3        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Additional payment of fee 900,000      
License Agreement | New Drug Application        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Additional payment of fee $ 1,000,000